A Study of Varipulse Catheter in Participants With Paroxysmal Atrial Fibrillation Under Optimized Sedation
NCT07511166
Arrhythmias, Cardiac, Atrial Fibrillation
View Trial DetailsNCT Number: NCT05381805
Treatment recommendations and guidelines for patients with atrial fibrillation (AF) are continuously changing. The role of catheter ablation in the treatment of AF increases and the techniques of the procedures are improving unceasingly. Responding to and evaluating the effect of these changes requires careful examination of this patient population and procedure outcomes. The aim is to create a clinical characterization platform for patients scheduled for AF ablations with the purpose to optimize health care processes and related translational research.
Trial opening soon.
Get Notified18 year–99 year
All sexes
Observational
Study design: Prospective cohort study and research platform of patients referred for AF ablation. Clinical characteristics and results of routine tests and procedures before, during and after AF ablation are collected. In addition, the following (non-standard) tests are performed: extended surface electrocardiogram (extECG), extended rhythm monitoring, biomarker testing, genetic analysis, and questionnaires. In subgroups of patients transesophageal electrocardiogram (TE-ECG), epicardial electroanatomical mapping and/or left atrial appendage (LAA) biopsy is performed.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
A subject who meets any of the following criteria will be excluded from the subset in whom additional consent for transesophageal ECG-imaging is asked:
A subject who meets any of the following criteria will be excluded from the subset in whom additional consent for transesophageal ECG (TE-ECG) is asked:
A subject who meets any of the following criteria will be excluded from the subset in whom additional consent for Cardiovascular Magnetic Resonance (ISOLATION CMR) is asked:
A subject who meets any of the following criteria will be excluded from the subset in whom additional consent for concomitant hybrid ablation of atrial fibrillation (COMBAT-AF) is asked:
Specific exclusion criteria for epicardial mapping (only applicable for patients undergoing hybrid or surgical AF ablation):
Time frame: 12 months
Freedom from documented recurrence of atrial arrhythmia after 12 months. Recurrences in the first 3 months after the index procedure (blanking period) are exempted.
Time frame: 3 to 24 months
Time to recurrence of AF or other atrial arrhythmia after the blanking period of 3 months.
Time frame: 0 to 3 months
Defined as any episode of documented arrhythmia during the blanking period, defined as within 3 months
Time frame: 0 to 24 months
Disease progression to persistent or permanent AF. Persistent AF is defined as AF that lasts longer than 7 days. Permanent AF can't be corrected with treatments.
Time frame: 0 to 24 months
Use of antiarrhythmic drugs (AADs) one year after ablation
Time frame: 0 to 24 months
Change in circulating biomarker for substrate quantification.
Time frame: 0 to 24 months
Change in circulating biomarker for substrate quantification.
Time frame: 0 to 24 months
Change in circulating biomarker for substrate quantification.
Time frame: 0 to 24 months
Change in circulating biomarker for substrate quantification.
Time frame: 0 to 24 months
Change in circulating biomarker for substrate quantification.
Time frame: 0 to 24 months
Change in circulating biomarker for substrate quantification.
Time frame: 0 to 24 months
Change in circulating biomarker for substrate quantification.
Time frame: 0 to 24 months
Change in circulating biomarker for substrate quantification.
Time frame: 0 to 24 months
Defined as repeated ablation procedure with the goal to prevent recurrence of AF or reduce the AF burden after one or more previous attempts to achieve the same goal.
Time frame: 0 to 24 months
Number of veins with pulmonary vein reconnection at redo procedure.
Time frame: 0 to 24 months
Major adverse cardiovascular events (MACE).
Time frame: Intraoperative
Defined as skin-to-skin time (time from initial femoral vein puncture to time of removal of sheaths).
Contact information is provided by the study sponsor or research team.
Dominique Verhaert, MD
CONTACT
Zarina Habibi, MD
CONTACT
Maastricht University Medical Center
Other
Intensive (Pre)Clinical Characterization of Patients undergOing Atrial fibrillATion ablatlON: a Multicenter Clinical Care and Research Platform
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07511166
Arrhythmias, Cardiac, Atrial Fibrillation
View Trial DetailsNCT07625215
Arrhythmias, Cardiac, Atrial Fibrillation
San Francisco, California, United States
View Trial DetailsNCT07560644
Arrhythmias, Cardiac, Atrial Fibrillation
View Trial DetailsNCT07724301
Arrhythmias, Cardiac, Atrial Fibrillation
View Trial Details